Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

4.8%

2 terminated out of 42 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

17%

7 trials in Phase 3/4

Results Transparency

55%

6 of 11 completed with results

Key Signals

6 with results85% success

Data Visualizations

Phase Distribution

33Total
Not Applicable (9)
Early P 1 (3)
P 1 (6)
P 2 (8)
P 3 (6)
P 4 (1)

Trial Status

Recruiting14
Completed11
Not Yet Recruiting9
Unknown4
Terminated2
Withdrawn1

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (42)

Showing 20 of 20 trials
NCT07569380Not Yet RecruitingPrimary

Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only Treatment

NCT07285213Phase 2RecruitingPrimary

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT05612672Not ApplicableActive Not RecruitingPrimary

Evaluation of GeoHAI Implementation

NCT06884748Early Phase 1Not Yet RecruitingPrimary

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06237452Phase 3Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT07496502Phase 1CompletedPrimary

Effect of Oral Microbiota on MDRO Decolonization

NCT04781387Phase 2CompletedPrimary

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

NCT05304715Phase 2CompletedPrimary

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

NCT06306014Phase 1RecruitingPrimary

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

NCT05852587Phase 1Not Yet Recruiting

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT07401680Phase 1Not Yet Recruiting

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

NCT05330182Phase 2RecruitingPrimary

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT06639997Phase 1CompletedPrimary

Safety and Tolerability of AZD5148 in Japanese Participants

NCT07374094RecruitingPrimary

Clostridioides Difficile: Understanding Responses and Treatment Effects

NCT06799039Early Phase 1Not Yet Recruiting

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

NCT06794944Phase 4Not Yet Recruiting

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

NCT06979609Phase 2RecruitingPrimary

Secondary Prevention of Clostridioides Difficile Using Vancomycin

NCT05266807Phase 3RecruitingPrimary

Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence

NCT07120490Not ApplicableNot Yet RecruitingPrimary

STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection

NCT06948461Phase 2Not Yet Recruiting

A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.

Scroll to load more

Research Network

Activity Timeline